



2005

Erratum: (Journal of Food and Drug Analysis vol. 12 (4) (344))

Follow this and additional works at: <https://www.jfda-online.com/journal>

Recommended Citation

SKIP (2005) "Erratum: (Journal of Food and Drug Analysis vol. 12 (4) (344))," *Journal of Food and Drug Analysis*: Vol. 13 : Iss. 2 , Article 8.

Available at: <https://doi.org/10.38212/2224-6614.2536>

This Corrigendum is brought to you for free and open access by Journal of Food and Drug Analysis. It has been accepted for inclusion in Journal of Food and Drug Analysis by an authorized editor of Journal of Food and Drug Analysis.

Polymorphisms of the Gene Encoding Multidrug Resistance Protein 1 in Taiwanese

MAY-JEN HUANG¹, YUNG-LIANG CHEN², CHANG-YU CHANG², YANG-YANG HUANG¹
AND CHING-SHAN HUANG^{1,3*}

¹ Department of Laboratory Medicine, Cathay General Hospital, Taipei, Taiwan, R.O.C.

² Department of Medical Technology and Institute of Biotechnology of Yuan-Pei University of Science and Technology, Hsinchu, Taiwan, R.O.C.

³ Department of Medical Technology, Fooyin University, 151 Chin-Hsueh Rd., Ta-Liao Township, Kaohsiung County 831, Taiwan, R.O.C.

(Received: August 11, 2004, Accepted: February 26, 2005)

ABSTRACT

Multidrug resistance protein 1 (MDR1) is one of the most important phase-3 proteins for detoxification. We hypothesized that the allele frequencies of polymorphisms in the *MDR1* gene in Taiwanese are different from those in other ethnic groups. The polymorphisms of A-41G, C-145G, T307C, G1199A, C1236T, G2677T, G2995A, and C3435T for the *MDR1* gene were determined for 110 healthy Taiwanese adults using restriction fragment length polymorphism of PCR product and the enzymes TspR I, Stu I, Hae II, Pst I, Hae III, BseY I, BstZ17 I, and Mbo I. The results showed that all the study subjects carried the wild type at nucleotides 307, 1199, and 2995. The frequencies of the heterozygous and homozygous variations were 17.3% and 0.0%, 15.5% and 2.7%, 50.0% and 39.1%, 56.4% and 28.2%, and 45.5% and 14.5% at nucleotides -41, -145, 1236, 2677, and 3435, respectively. Compared with previous reports, for Taiwanese, the allele frequencies of polymorphisms in the *MDR1* gene were significantly different from Japanese, Caucasians, Africans, Chinese living in Singapore, and Chinese living in Mainland China; except for those of -41G (identical to Japanese), 1236T, and 2677T (identical to Chinese living in Singapore). In conclusion, differences in allele frequencies for polymorphisms in the *MDR1* gene were observed for Taiwanese in comparison with other ethnic groups and Chinese living in Singapore and Mainland China.

Key words: *MDR1* gene, single nucleotide polymorphism, PCR-RFLP

INTRODUCTION

The three phases of detoxification are oxidation (phase 1), conjugation (phase 2), and transportation (phase 3). The oxidation reaction is mainly catalyzed by cytochrome P (CYP) 450, while UDP-glucuronosyltransferase (UGT) is the major enzyme in the conjugation reaction, with a number of proteins responsible for the transportation of toxic metabolites⁽¹⁻³⁾. Of these three detoxification phases, oxidation has been mostly studied, while conjugation and transportation are potential fields of research in the 21st century.

In Taiwan, CYP 450 polymorphism has been studied since 1993⁽¹⁾; by contrast, research on UGT and transportation has only commenced recently. Since 2000 seven research papers on the *UGT1A1* gene in Taiwanese have been published⁽⁴⁻¹⁰⁾. By contrast, the study of *UGT1A7* gene in Taiwanese is in its infancy⁽¹¹⁾. The results of the previous studies indicate that, for the *UGT1A1* gene the frequency of the A(TA)₇TAA allele in the promoter area is lower and the rate of variation within the coding region much higher, for Taiwanese as compared with Caucasians^(4,6-10,12-14). Further, the allele frequencies for single nucleotide polymorphisms (SNPs) in *UGT1A7* are different for these two ethnicities^(11,15).

The multidrug resistance protein 1 (*MDR1*) gene product, P-glycoprotein, is one of the most important ATP-binding transporters and one of the most important proteins for phase 3 detoxification^(16,17). The *MDR1* gene is located on chromosome 7q21 and consists of 28 exons, encoding a 1280 amino acid transporter⁽¹⁶⁾. To date, 28 SNPs in the promoter and exons of the *MDR1* gene have been reported and it has been demonstrated that seven of these are associated with variation of P-glycoprotein function⁽¹⁸⁾. We hypothesized that the allele frequencies for the polymorphisms in the *MDR1* gene in Taiwanese are different from those in other ethnic groups and then performed this study to investigate the eight known SNPs of the *MDR1* gene for Taiwanese. To the best of our knowledge, this is the first report to investigate so many SNPs in the *MDR1* gene in the Chinese ethnic group.

MATERIALS AND METHODS

I. Study Subjects

The study subjects, consisted of 110 random-collected healthy Taiwanese adults (55 male and 55 female), representing part of general populations whose ancestors came from Fukien province. Every subject gave written consent to participate in this study.

* Author for correspondence. Tel: +886-2-26360450,
E-mail: chsh.huang@msa.hinet.net

Table 1. Primers and mutagenesis primers for PCR of the human *MDR1* gene

SNP Site	Exon	Primer	
A-41G	Promoter	Forward	5'-CTCCTAGCCTTTTCAAAGGTG-3'
		Reverse	5'-CAGGTTGAATTTCCAGGAGG-3'
C-145G	Promoter	Forward	5'-GCTCTCTTTGCCACAGGAGG-3' ^a
		Reverse	5'-CCTGACACTTGGGAAGGTC-3'
T307C	5	Forward	5'-GGTGATATCAATGATACAGCG-3' ^a
		Reverse	5'-CTAAAACTATCAAGTGTATTG-3'
G1199A	11	Forward	5'-GGAATTCAGAAATGTTCACTGCA-3' ^a
		Reverse	5'-GGAAGTACTGTTCACTAGG-3'
C1236T	12	Forward	5'-TCTATTGAATGAAGAGTTTCTG-3'
		Reverse	5'-CACTCTGCACCTTCAGGTTTC-3'
G2677T	21	Forward	5'-TATCCTTCATCTATGGTTGG-3'
		Reverse	5'-TTTAGTTTGACTCACCTCCC-3'
G2995A	24	Forward	5'-CAGTTCATTTGCTCCTGAGTA-3' ^a
		Reverse	5'-CAGTTGAAACATCAAATCACC-3'
C3435T	26	Forward	5'-GTTTTCAGCTGCTTGATGGC-3'
		Reverse	5'-CATTAGGCAGTGACTCGATG-3'

^aUnderscoring indicates mutagenesis site.

Table 2. Restriction enzymes for digestion of PCR products

Region	Restriction enzyme	PCR fragment (base pair)	Restriction band (base pair)
A-41 G	TspR I	276	175; 82; 19 [variant]
C-145G	Stu I	211	191; 20 [wild type]
T307C	Hae II	176	154; 22 [variant]
G1199A	Pst I	166	142; 24 [wild type]
C1236T	Hae III	173	150; 23 [wild type]
G2677T	BseY I	155	132; 23 [wild type]
G2995A	BstZ17 I	133	112; 21 [variant]
C3435T	Mbo I	216	159; 57 [wild type]




Figure 1. Example results for digestion of PCR fragment for C3435T *MDR1* gene. M: DNA size markers; 1: homozygous variation; 2: heterozygous variation; and 3: wild type. The DNA sizes are 216 bp in lane 1; 216 bp (top), 159 bp (intermediate), and 57 bp (bottom) in lane 2; and 159 bp (upper) and 57 bp (lower) in lane 3, respectively.

II. Determination of *MDR1* Gene

The A-41G, C-145G, T307C, G1199A, C1236T, G2677T, G2995A, and C3435T polymorphisms were determined for the *MDR1* gene using method of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Total genomic DNA was isolated from the blood cells using a blood DNA isolation kit (Maxim Biotech Inc; San Francisco, USA). The primers and mutagenesis primers used for PCR to determine these eight

variants are presented in Table 1. The amplification reaction mixture (100 μ L) contained 1 μ g of DNA in 10 mM Tris-HCl (pH = 8.8), 1.5 mM MgCl₂, 50 mM KCl, 0.1% Triton X-100, 200 μ M of each dNTP, 100 ng of each primer, and 2U of Dynazyme DNA polymerase (Finnzymes OY; Espoo, Finland). The reaction was performed using a DNA thermal cycler (Perkin-Elmer Cetus; Norwalk, CT, USA) for 35 cycles of: denaturation for 60 sec at 94°C, annealing for 60 sec at 55°C, primer extension for 60 sec at 72°C, with a final 10-min extension at 72°C. The PCR product was digested with the appropriate restriction enzymes (TspR I, Stu I, Hae II, Pst I, Hae III, BseY I, BstZ17 I, and Mbo I; Table 2), and analyzed on 3% agarose gel (NuSieve 3:1, Cambrex Bio Science Rockland Inc.; Rockland, ME, USA) containing ethidium bromide.

III. Statistical Analysis

The allele frequencies of the *MDR1* genotypes for our study subjects were compared with those for other ethnic groups and with Chinese living in Singapore and Mainland China⁽¹⁸⁻²³⁾ using the chi-square test. A *p* value < 0.05 was defined as statistically significant.

RESULTS

The PCR-RFLP method identified wild type, heterozygous or homozygous variation at the eight polymorphic sites. For example (Figure 1), the Mbo I digestion of the PCR fragment from the homozygous variation at nucleotide 3435 yielded one band of 216 base pair (bp), while the Mbo I digestion of the PCR products from individuals carrying wild type and heterozygous variations resulted in two (159 and 57 bp) and three bands (216, 159 and 57 bp), respectively.

Table 3 shows the number and frequency of genotypes of the *MDR1* gene determined for the study sample. All

110 individuals carried the wild type at nucleotides 307, 1199, and 2995. Less than 20% of the subjects bore variations at nucleotides -41 and -145, while variation at nucleotide 3435 was determined for 60% of the sample, and more than 80% were carriers of variants for nucleotides 1236 and 2677. All 50 subjects with heterozygous variation at nucleotide 3435 also carried heterozygous C1236T and G2677T variations, and all 16 with homozygous C3435T bore homozygous C1236T and G2677T variations (data not shown in Tables). The allele frequency of a variant was calculated by: $(2 \times \text{number of subjects with homozygous variation}) + (1 \times \text{number of subjects with heterozygous variation})$ and then divided by (2×110) . For example, allele frequency of 3435T: $[(2 \times 16) + (1 \times 50)]/220 = 82/220 = 37.3\%$. Table 4 compares the allele frequencies for Taiwanese and other ethnic groups and the Chinese living in Singapore and Mainland China. Between Taiwanese and Japanese, the allele frequencies for -145G, 1236T, 2677T, and 3435T ($p < 0.05$) were significantly different, but not for -41G ($P = 0.88$). Comparing allele frequencies with Taiwanese, highly significant differences ($p < 0.001$) were demonstrated for Caucasians for 1236T, 2677T and 3435T and for Africans for 3435T. In comparison with Chinese living in Singapore and Mainland China, the allele frequencies of 1236T and 2677T for Taiwanese were not significantly different, while that for 3435T was.

DISCUSSION

P-glycoprotein transports a wide range of lipophilic and amphiphatic substances, such as anticancer agents, cardiac drugs, HIV protease inhibitors, immunosuppressants, and β -adrenoceptor antagonists⁽¹⁶⁻¹⁸⁾. This protein was found in 1976 and its gene (*MDR1*) was cloned in 1986, with the first SNP (C3435T) described in 2000⁽²⁴⁾. Recent experimental findings strongly implicate P-glycoprotein as: a determinant of homeostatic interaction between bacteria and host in humans, a factor in the pathogenesis of inflammatory bowel disease⁽²⁵⁾, playing an important role in the tumorigenesis of colon cancer⁽²⁶⁾, a susceptibility factor for development of renal epithelial tumors⁽²⁷⁾, and a genetic factor determining earlier onset of Parkinson's disease symptoms⁽²⁸⁾. The results of studies exploring the relationship between *MDR1* polymorphisms and clinical outcome have demonstrated that: AIDS patients with the 3435 TT genotypes have superior outcomes relative to patients carrying 3435 CT or CC⁽²⁹⁾, acute-lymphoblastic-leukemia patients bearing the 3435 CT/TT genotypes have a significantly lower rate of CNS relapse compared to the CC group⁽³⁰⁾, and presence of two T alleles at position 3435 was associated with a higher risk for occurrence of postural hypotension in nortriptyline-treated patients in comparison with those patients with the 3435 CC/CT genotypes⁽³¹⁾. Very recently, several studies

Table 3. Number and frequency (%) for genotypes of the *MDR1* gene in the 110 subjects

SNP	Heterozygous variation		Homozygous variation		Wild type	
	Number	Frequency	Number	Frequency	Number	Frequency
A-41G	19	17.3	0	0.0	91	82.7
C-145G	17	15.5	3	2.7	90	81.8
T307C	0	0.0	0	0.0	110	100.0
G1199A	0	0.0	0	0.0	110	100.0
C1236T	55	50.0	43	39.1	12	10.9
G2677T	62	56.4	31	28.2	17	15.4
G2995A	0	0.0	0	0.0	110	100.0
C3435T	50	45.5	16	14.5	44	40.0

Table 4. The comparison for allele frequencies of *MDR1* gene between Taiwanese and other ethnic groups using the chi-squared test (*P*-value)

Ethnicity	Number of chromosome	Allele frequency (%)				
		-41G	-145G	1236T	2677T	3435T
Taiwanese	220	8.6	10.5	64.1	56.4	37.3
Japanese ⁽¹⁹⁾	200	9.4	1.0	35.4	41.7	49.0
<i>P</i> -value		0.88	< 0.001	< 0.001	0.004	0.02
Caucasians ⁽²³⁾	922			41.0	41.6	53.9
<i>P</i> -value				< 0.001	< 0.001	< 0.001
Africans ⁽²²⁾	412					17.0
<i>P</i> -value						< 0.001
Chinese in Singapore ⁽²⁰⁾	192			71.9	50.0	53.1
<i>P</i> -value				0.09	0.41	0.002
Chinese in Singapore ⁽²¹⁾	196					54.0
<i>P</i> -value						< 0.001
Chinese in Mainland ⁽²²⁾	264					46.6
<i>P</i> -value						0.04

have revealed that the *MDR1* gene is highly associated with therapeutic response in some life-threatening diseases. Patients with drug-resistant epilepsy were found to be more likely to have the CC genotype of the *MDR1* gene than the TT genotype⁽³²⁾. In kidney transplant recipients, C3435T and G2677T/A polymorphism of the *MDR1* gene decreased the risk for steroid-induced osteonecrosis of the femoral head⁽³³⁾, and tacrolimus dose requirement was 40% higher for those with homozygous C2677T in comparison with patients bearing the wild-type variant for this SNP⁽³⁴⁾. In a sample of irinotecan-treated individuals, there was a significant association between carriage of C1236T, G2677T and C3435T and reduced renal clearance of those compounds⁽³⁵⁾.

Since the importance of *MDR1* gene variations has been proven, studies of this gene have been performed in several ethnic groups. Ethnic differences in the allele frequency of the variant *MDR1* gene have been observed. For example, the frequency of individuals homozygous for the C and T allele at nucleotide 3435 in European and American Caucasians, respectively, is approximately 25% for each genotype and the TT genotype has a frequency of only 6% in Africans⁽²²⁾. However, similar examples for other SNPs are limited. The frequency of the 2677T allele is reportedly 42%, 41.7%, and 13% in Germans, Japanese, and African Americans, while the frequency of Caucasians homozygous for the 1236TT is about one-third the value of Japanese (13.3% versus 37.5%)^(19,23). Moreover, some variations are only found in single ethnic groups. For instance, the SNP at nucleotide 3421 has only been observed in Ghanaian populations and African Americans (1.2% and 4.3%, respectively), and not Caucasians⁽³⁶⁾, while those at nucleotides -41 and -145 in exon 1 have been found in Japanese (7.3% and 1.0% for A-41G and C-145G, respectively), but not Caucasians and Africans⁽¹⁹⁾.

To date, there have been three investigations of the *MDR1* gene in Chinese, one of C3435T, C1236T, and G2677T for Chinese living in Singapore⁽²⁰⁾, and the other two of C3435T for Chinese living in Singapore⁽²¹⁾ and Chinese living in Mainland China⁽²²⁾. In this study, we investigated eight SNPs of the *MDR1* gene, including six of the seven SNPs affecting P-glycoprotein function⁽¹⁸⁾, as well as the two promoter-area SNPs found in Japanese⁽¹⁹⁾. Our results indicate that, in Taiwanese the allele frequencies of polymorphisms in the *MDR1* gene are significantly different from those in Japanese, Caucasians, and Africans, except for that for -41G (identical to Japanese). When compared with Chinese living in Singapore and Mainland China, our data show that the allele frequency of 3435T is different while those for 1236T and 2677T are identical. The findings may be explained, at least partially, by that the specimens for the investigation of *MDR1* gene for the Chinese living in Mainland China were collected from Chengtu (in Szechwan province) populations⁽²²⁾ and the origin of Chinese living in Singapore is mainly from Canton province, while our Taiwanese study subjects whose ancestors came from Fukien province of Mainland China.

The most important findings are that the frequency (14.5%) of 3435TT in Taiwanese is in between that in Africans (6%) and in Americans (25%) and the frequency of 3435T carriage for Taiwanese varies from that reported for other ethnic groups. We can conclude, therefore, that significant inter-ethnicity differences exist in the *MDR1* gene, as confirmed by other authors^(19,22,23,36). We also found that C3435T is in linkage disequilibrium with C1236T and G2677T, in line with other reports^(18,19,28,33-36). Inter-ethnic variation in the incidence of *MDR1* polymorphisms may contribute to racial differences in drug response and disease susceptibility, distinguishing Taiwanese from individuals of other ethnic origins.

Most of the P-glycoprotein substrates are also metabolized by CYP3A4, the major drug-eliminating enzyme⁽²⁰⁾. P-glycoprotein and CYP3A4 work in tissues, such as small intestine and liver, in a coordinate fashion in order to prevent entry of orally ingested xenobiotics into the body. Interestingly, CYP3A4 polymorphisms are rare in Asian populations (< 1.8% in Chinese, Japanese, Malays, and Indians)⁽²⁰⁾. On the other hand, the results of several studies⁽²⁰⁻²²⁾ as well as our own show that Chinese carry a relatively higher frequency (up to 71.9%) of *MDR1* polymorphisms. Those differences may indicate that, in Chinese, the variant *MDR1* gene plays a more important role than the variant CYP3A4 gene in terms of elimination of xenobiotics. It appears reasonable to suggest, therefore, that the relationship between SNPs of the *MDR1* gene and the metabolism of its substrates in Taiwanese merits further study. A research program of this type is ongoing at our laboratory.

ACKNOWLEDGEMENTS

This study was supported by a grant from Cathay General Hospital, Taipei, Taiwan.

REFERENCES

1. Wang, S. L., Huang, J. D., Lai, M. D., Liu, B. H. and Lai, M. L. 1993. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. *Clin. Pharmacol. Therap.* 53: 410-418.
2. Radomska-Pandya, A., Czernik, P. J., Little, J., Battaglia, E. and Mackenzie, P. I. 1999. Structural and functional studies of UDP-glucuronosyltransferases. *Drug Metab. Rev.* 31: 817-899.
3. Jansen, P. L. 2000. Foreword: from classic bile physiology to cloned transporters. *Sem. Liver Dis.* 20: 245-250.
4. Huang, C. S., Luo, G. A., Huang, M. J., Yu, S. C. and Yang, S. S. 2000. Variations of the bilirubin uridine-diphospho-glucuronosyltransferase 1A1 gene in healthy Taiwanese. *Pharmacogenetics* 10: 539-544.

5. Huang, C. S., Luo, G. A., Huang, M. J., Chen, E. S., Young, T. H. and Chao, Y. C. 2001. A novel compound heterozygous variation of the UDP-glucuronosyltransferase 1A1 gene that causes Crigler-Najjar syndrome type II. *Pharmacogenetics* 11: 639-642.
6. Hsieh, S. Y., Wu, Y. H., Lin, D. Y., Chu, C. M., Wu, M. and Liaw, Y. F. 2001. Correlation of mutational analysis to clinical features in Taiwanese patients with Gilbert's syndrome. *Am. J. Gastroenterol.* 96: 1188-1193.
7. Huang, C. S., Chang, P. F., Huang, M. J., Chen, E. S. and Hung, K. L. 2002. Relationship between bilirubin UDP-glucuronosyltransferase 1A1 gene and neonatal hyperbilirubinemia. *Pediatr. Res.* 52: 601-605.
8. Huang, C. S., Chang, P. F., Huang, M. J., Chen, E. S. and Chen, W. C. 2002. Glucose-6-phosphate dehydrogenase deficiency, the UDP-glucuronosyltransferase 1A1 gene and neonatal hyperbilirubinemia. *Gastroenterology* 123: 127-133.
9. Huang, M. J., Yang, Y. C., Yang, S. S., Lin, M. S., Chen, E. S. and Huang, C. S. 2002. Co-inheritance of variant UDP-glucuronosyltransferase 1A1 gene and glucose-6-phosphate dehydrogenase deficiency in adults with hyperbilirubinemia. *Pharmacogenetics* 12: 663-666.
10. Huang, M. J., Kua, K. E., Teng, H. C., Tang, K. S. and Huang, C. S. 2004. Risk factors for severe hyperbilirubinemia in neonates. *Pediatr. Res.* 56: 682-689.
11. Huang, M. J., Yang, S. S., Lin, M. S. and Huang, C. S. 2005. Polymorphisms of the UDP-glucuronosyltransferase 1A7 gene in Taiwan Chinese. *World J. Gastroenterol* 11: 797-802.
12. Bosma, P. J., Chowdhury, J. R., Bakker, C. T., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N., Jansen, P. L. and Oude-Elferink, R. P. 1995. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. *New Engl. J. Med.* 333: 1171-1175.
13. Monaghan, G., Foster, B., Jurima-Romet, M., Hume, R., Burchell, B. and Owens, I. S. 1997. UGT1*1 genotyping in a Canadian Inuit population. *Pharmacogenetics* 7: 153-156.
14. Beutler, E., Gelbart, T. and Demina, A. 1998. Racial variability in the UDP-glucuronosyltransferase 1 (*UGT1A1*) promoter: a balanced polymorphism for regulation of bilirubin metabolism? *Proc. Natl. Acad. Sci. USA* 95: 8170-8174.
15. Guillemette, C., Ritter, J. K., Auyeung, D. J., Kessler, F. K. and Housman, D. E. 2000. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human *UGT1A7* gene. *Pharmacogenetics* 10: 629-644.
16. Chen, C. J., Clark, D., Ueda, K., Pastan, I., Gottesman, M. M. and Roninson, I. B. 1990. Genomic organization of the human multidrug resistance (*MDR1*) gene and origin of p-glycoproteins. *J. Biol. Chem.* 265: 506-514.
17. de Lannoy, I. A. M. and Silverman, M. 1992. The *MDR1* gene product, p-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. *Biochem. Biophys. Res. Commun.* 30: 551-557.
18. Eichelbaum, M., Fromm, M. F. and Schwab, M. 2004. Clinical aspects of the *MDR1* (*ABCB1*) gene polymorphism. *Ther. Drug Monit.* 26: 180-185.
19. Tanabe, M., Ieiri, I., Nagata, N., Inoue, K., Ito, S., Kanamori, Y., Takahashi, M., Kurata, Y., Kigawa, J., Higuchi, S., Terakawa, N. and Otsubo, K. 2001. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (*MDR*)-1 gene. *J. Pharmacol. Exp. Ther.* 297: 1137-1143.
20. Chowbay, B., Cumaraswamy, S., Cheung, Y. B., Zhou, Q. and Lee, E. J. D. 2003. Genetic polymorphisms in *MDR1* and *CYP3A4* genes in Asians and the influence of *MDR1* haplotypes on cyclosporin disposition in heart transplant recipients. *Pharmacogenetics* 13: 89-95.
21. Balram, C., Sharma, A., Sivathanan, C. and Lee, E. J. D. 2003. Frequency of C3435T single nucleotide *MDR1* genetic polymorphism in an Asian population: phenotypic-genotypic correlates. *Br. J. Clin. Pharmacol.* 56: 78-83.
22. Ameyaw, M. M., Regateiro, F., Li, T., Liu, X., Tariq, M., Mobarek, A., Thornton, N., Folayan, G. O., Githang, A. J., Indalo, A., Ofori-Adjei, D., Price-Evans, D. A. and McLeod, H. L. 2001. *MDR1* pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. *Pharmacogenetics* 11: 217-221.
23. Cascorbi, I., Gerloff, T., Johne, A., Meisel, C., Hoffmeyer, S., Schwab, M., Schaeffeler, E., Eichelbaum, M., Brinkmann, U. and Roots, I. 2001. Frequency of single nucleotide polymorphism in the p-glycoprotein drug transporter *MDR1* gene in white subjects. *Clin. Pharmacol. Ther.* 69: 169-174.
24. Hoffmeyer, S., Burk, O., Richter, O. V., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. and Brinkmann, U. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity *in vivo*. *Proc. Natl. Acad. Sci. USA* 97: 3473-3478.
25. Farrell, R. J., Murphy, A., Long, A., Donnelly, S., Cherikuri, A., O'Toole, D., Mahmud, N., Keeling, P. W., Weir, D. G. and Kelleher, D. 2000. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. *Gastroenterology* 118: 279-288.
26. Potocnik, U., Ravnik-Glavac, M., Golouh, R. and Glavac, D. 2002. Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. *J. Med. Genet.* 39: 340-346.
27. Siegsmond, M., Brinkmann, U., Schaeffeler, E., Weirich, G., Schwab, M., Eichelbaum, M., Fritz, P.,

- Burk, O., Decker, J., Alken, P., Rothenpieler, U., Kerb, R., Hoffmeyer, S. and Brauch, H. 2002. Association of the P-glycoprotein transporter *MDR1* (C3435T) polymorphism with the susceptibility to renal epithelial tumors. *J. Am. Soc. Nephrol.* 13: 1847-1854.
28. Furuno, T. Landi, M. T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M. and Zanger, U. M. 2002. Expression polymorphism of the blood-brain barrier component P-glycoprotein (*MDR1*) in relation to Parkinson's disease. *Pharmacogenetics* 12: 529-534.
29. Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J. P., Decosterd, L. A., Furrer, H. and Telenti, A. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variations of the multidrug resistance transporter 1: a pharmacogenetics study. *Lancet* 359: 30-36.
30. Stanulla, M., Schaeffeler, E., Schrappe, M., Rathmann, A., Arens, S., Welte, K., Eichelbaum, M., Zanger, U. and Schwab, M. 2001. An association between the *MDR1* C3435T polymorphism and CNS relapse in childhood acute lymphoblastic leukemia. *Blood* 98: 317 a (Abstr.).
31. Roberts, R., Joyce, P., Mulder, R. T., Begg, E. J. and Kennedy, M. A. 2002. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypertension in patients treated for major depression. *Pharmacogenomics* 12: 191-196.
32. Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B., Wood, N. W. and Sisodiya, S. M. 2003. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. *New Eng. J. Med.* 348: 1442-1448.
33. Asano, T., Takahashi, K. A., Fujioka, M., Inoue, S., Okamoto, M., Sugioka, N., Nishino, H., Tanaka, T., Hirota, Y. and Kubo, T. 2003. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. *Pharmacogenetics* 13: 675-682.
34. Anglicheau, D., Verstuyft, C., Laurent-Puig, P., Becqemont, L., Schlageter, M. H., Cassinat, B., Beaune, P., Legendre, C. and Thervet, E. 2003. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. *J. Am. Soc. Nephrol.* 14: 1889-1896.
35. Sai, K., Kaniwa, N., Itoda, M., Saito, Y., Hasegawa, R., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Shirao, K., Minami, H., Ohtsu, A., Yoshida, T., Saijo, N., Kitamura, Y., Kamatani, N., Ozawa, S. and Sawada, J. I. 2003. Haplotype analysis of ABCB1/*MDR1* blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. *Pharmacogenetics* 13: 741-757.
36. Kim, R. B., Leake, B. F., Choo, E. F., Dresser, G. K., Kubba, S. V., Schwarz, U. I., Taylor, A., Xie, H. G., McKinsey, J., Zhou, S., Lan, L. B., Schuetz, J. D., Schuetz, E. G. and Wilkinson, G. R. 2001. Identification of functionally variant *MDR1* alleles among European Americans and African Americans. *Clin. Pharmacol. Ther.* 70: 189-199.